On November 12th CEDMO Pharmaceuticals, which specializes in cell and gene therapy, announced the expansion of its cell and gene therapy research and development platform to provide customers with high-quality and cost-effective research and development and GMP granule DNA production services.
is committed to providing integrated, end-to-end cell and gene therapy research and development services for the biopharmaceutical industry.
the expansion of its services, Therminic Foundation can directly help customers around the world address supply constraints on prosite DNA, enabling customers to accelerate the early entry of innovative therapies to the market for the benefit of patients.
biopharmaceutical companies developing high-end therapeutic drugs have a reliable and controlled supply chain of granulated DNA that better protects their clinical research and commercial production of raw materials.
pharmaceutical company is able to provide customers with "one-stop" solutions from protons to viral vectors, delivering viral vectors for research and development, clinical research and commercialization in a short period of time, driving cell and gene therapy applications.
In order to meet the growing demand for prosite DNA in the industry, Pharmaceuticals leverages its expertise in testing process raw materials and biologics, and ensures product purity and particle safety through its own quality control and analytical testing services, providing customers with prosite DNA products that meet GMP quality regulatory standards in the United States, the European Union and China.